Overview

Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

Status:
Active, not recruiting
Trial end date:
2023-12-30
Target enrollment:
0
Participant gender:
Female
Summary
This is an open, single-arm, phase I clinical trial to evaluate safety and efficacy and of 6b11-OCIK injection in the treatment of recurrent drug-resistant ovarian cancer
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Doxorubicin
Criteria
Inclusion criteria:

1. 18-70 years old patients.

2. Diagnosed as Ovarian Cancer, who had relapsed after initial treatment; Relapse after
drug resistance: clinical remission after early chemotherapy, but progression or
relapse within 6 months after chemotherapy,or achieve no response after early
chemotherapy.

3. Administered with Doxorubicin.

Exclusion criteria:

1. Symptomatic and uncontrolled Brain metastasis or pia meningeal metastasis; Patients
with spinal cord compression; Symptoms related to central nervous system lesions or
symptoms indicating disease progression;

2. Corticosteroid drugs (or analogues) or drugs effecting the immune system were
administered before infusion in 4 weeks.

3. Patients with interstitial lung disease or interstitial pneumonia, including
clinically significant radiation pneumonia;

4. Women with positive serum pregnancy test or lactation;